(NASDAQ: QNCX) Quince Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.07%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.04%.
Quince Therapeutics's earnings in 2026 is -$92,476,000.On average, 7 Wall Street analysts forecast QNCX's earnings for 2026 to be -$8,396,058, with the lowest QNCX earnings forecast at -$8,751,217, and the highest QNCX earnings forecast at -$8,009,371. On average, 7 Wall Street analysts forecast QNCX's earnings for 2027 to be -$4,626,823, with the lowest QNCX earnings forecast at -$6,089,970, and the highest QNCX earnings forecast at -$3,727,027.
In 2028, QNCX is forecast to generate -$4,260,273 in earnings, with the lowest earnings forecast at -$4,933,773 and the highest earnings forecast at -$3,897,894.